Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,046 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunity Clear all
Completed Phase 1 Interventional

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

NCT02840487
View directory record Official record
Conditions
Prevention of Zika Infection, Zika-Specific Immune Response
Interventions
VRC-ZKADNA085-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 6, 2026, 6:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 6, 2026, 6:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106
View directory record Official record
Conditions
Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions
Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
Biological
Lead sponsor
AC Immune SA
Industry
Eligibility
35 Years to 85 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
13
States / cities
Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 6, 2026, 6:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucocorticoid Effects on Cellular Cytokine Release

NCT00001415
View directory record Official record
Conditions
Depressive Disorder, Fatigue Syndrome, Chronic, Fibromyalgia, Healthy, Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 6:09 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

NCT06169150
View directory record Official record
Conditions
Nervous System Disease, Immune System Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 120 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2043
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 6, 2026, 6:09 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

NCT04980391
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 49 Years · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 6, 2026, 6:09 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 6, 2026, 6:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

NCT00510874
View directory record Official record
Conditions
Influenza
Interventions
Pumarix™, Pandemrix ™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 6, 2026, 6:09 AM EDT
Terminated Phase 3 Interventional Results available

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 6, 2026, 6:09 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913
View directory record Official record
Conditions
Smoke Exposure, Influenza
Interventions
LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 6, 2026, 6:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections

NCT00004996
View directory record Official record
Conditions
Healthy, Helminthiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 6, 2026, 6:09 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT07204964
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
15
States / cities
Guntersville, Alabama • Canoga Park, California • Walnut Creek, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 6, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 6, 2026, 6:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

NCT00589394
View directory record Official record
Conditions
Healthy
Interventions
pneumococcal vaccination (Pneumovax)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 6, 2026, 6:09 AM EDT
Completed No phase listed Observational Results available

Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

NCT01517529
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 6, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

NCT02866682
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 6, 2026, 6:09 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

NCT02385123
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 6, 2026, 6:09 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

NCT06064279
View directory record Official record
Conditions
Stage IV NSCLC
Interventions
Poly ICLC, IVIG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 6:09 AM EDT
Completed No phase listed Observational

Maternal Immunization: Giving Immunity For Tomorrow

NCT01496079
View directory record Official record
Conditions
Pregnancy, Influenza
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 6, 2026, 6:09 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity

NCT01421888
View directory record Official record
Conditions
Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency, Citrullinemia, Ornithine Carbamoyltransferase Deficiency, Hyperargininemia, N-Acetylglutamate Synthase Deficiency
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 6, 2026, 6:09 AM EDT
Completed Phase 4 Interventional

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

NCT03164967
View directory record Official record
Conditions
Humoral Immune Response
Interventions
Bivigam
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
2 Years to 16 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Centennial, Colorado • Durham, Florida • North Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 6, 2026, 6:09 AM EDT
Completed No phase listed Observational

CNS (Central Nervous System) Viral Dynamics and Cellular Immunity During AIDS

NCT00583167
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 6, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 6, 2026, 6:09 AM EDT
Completed Not applicable Interventional Results available

Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova

NCT01433471
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Trichuris suis ova
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 72 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 6, 2026, 6:09 AM EDT